Hsingming Liou
Internal Medicine · San Francisco, CANPI 1770678377
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,151, 5.0 times the $632 reported in 2019. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $121.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Sanofi$853
- Novo Nordisk$596
- AbbVie$491
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$422
- plus $5K from 27 others
What the payments were for
- Food & beverage$10,090100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 10 | $1,250 |
| Teva Pharmaceuticals USA, Inc. | 9 | $1,062 |
| Sanofi | 6 | $853 |
| Novo Nordisk | 6 | $596 |
| AbbVie | 4 | $491 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $422 |
| E.r. Squibb & Sons, L.L.C. | 3 | $375 |
| Amgen | 3 | $365 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $360 |
| Exelixis Inc. | 3 | $343 |
| Lilly USA, LLC | 3 | $330 |
| Fresenius Kabi USA, LLC | 2 | $268 |
| Bayer | 2 | $261 |
| Boehringer Ingelheim | 2 | $250 |
| AstraZeneca | 2 | $249 |
| Mirum Pharmaceuticals, Inc. | 2 | $248 |
| Gilead | 2 | $239 |
| Eisai Inc. | 2 | $238 |
| Biogen | 2 | $195 |
| Neurocrine Biosciences, Inc. | 1 | $171 |
| Dexcom, Inc. | 1 | $151 |
| Shire North American Group Inc | 1 | $143 |
| Kyowa Kirin, Inc. | 1 | $137 |
| Genentech USA, Inc. | 1 | $125 |
| Ferring Pharmaceuticals Inc. | 1 | $125 |
| Heron Therapeutics, Inc. | 1 | $125 |
| Almirall LLC | 1 | $125 |
| Astellas Pharma US Inc | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 1 | $119 |
| Dynavax Technologies Corporation | 1 | $117 |
| Shionogi Inc | 1 | $114 |
| Regeneron Healthcare Solutions, Inc. | 1 | $92 |
| Galderma Laboratories, L.p. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$820
- DUPIXENT$701
- Austedo XR$534
- SIMPONI ARIA$434
- CAPLYTA$422
- INVEGA$271
- INVEGA SUSTENNA$271
- Cabometyx$251
- Wegovy$249
- Livmarli$248
- LENVIMA$238
- EXKIVITY$235
- UZEDY$232
- INGREZZA$171
- Kabiven$154
- DEXCOM G7 GSS (161)$151
- LINZESS$150
- XARELTO$149
- ADVATE$143
- Kerendia$142
How this compares
$10,090 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- John TeerlinkSan Francisco$819K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.